Two SPACE-F Batch 7 incubated startups—Amaranth Labs and UPLI—are addressing emerging gaps in the food-tech sector driven by GLP-1 medication adoption. Amaranth Labs uses dry fractionation to extract differentiated protein streams from amaranth seeds for nutrient-dense formulations; UPLI employs precision fermentation to produce human milk proteins. The opportunity is not marketing GLP-1-specific products, but redesigning food to deliver adequate nutrition (amino acids, fiber, vitamins) in smaller portions, requiring ingredient innovation beyond simple high-protein claims.